公开(公告)号：EP3914698A1

公开(公告)日：2021-12-01

申请号：EP20704611.1

申请日：2020-01-23

申请人： Yeda Research and Development Co. Ltd

发明人： HANNA, Yaqub ,  NOVERSHTERN, Noa ,  SHANI, Tom Haim ,  VIUKOV, Sergey ,  MASSARWA, Rada ,  BAYERL, Jonathan ,  AYYASH, Muneef

IPC分类号： C12N5/0735 ,  C12N5/074

公开(公告)号：EP3194572A1

公开(公告)日：2017-07-26

申请号：EP15759548.9

申请日：2015-07-30

申请人： Yeda Research and Development Co. Ltd.

发明人： HANNA, Yaqub ,  NOVERSHTERN, Noa ,  RAIS, Yoach

IPC分类号： C12N5/0735 ,  C12N5/074 ,  C12N15/00

CPC分类号： C12N5/0696 ,  C12N5/0037 ,  C12N5/0606 ,  C12N2500/38 ,  C12N2500/90 ,  C12N2501/01 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/235 ,  C12N2501/415 ,  C12N2501/50 ,  C12N2501/60 ,  C12N2501/71 ,  C12N2501/72 ,  C12N2501/727 ,  C12N2501/73 ,  C12N2501/999 ,  C12N2506/00

摘要： A culture medium is disclosed which comprises STAT3 activator, an ERK1/2 inhibitor and an Axin stabilizer, and optionally also a PKC inhibitor. Cell cultures comprising same and uses thereof are also disclosed.

摘要翻译： 公开了包含STAT3激活剂，ERK1 / 2抑制剂和Axin稳定剂以及任选还有PKC抑制剂的培养基。 还公开了包含其的细胞培养物及其用途。

公开(公告)号：EP2989199A1

公开(公告)日：2016-03-02

申请号：EP14727237.1

申请日：2014-04-23

申请人： Yeda Research and Development Co., Ltd.

发明人： HANNA, Yaqub ,  NOVERSHTERN, Noa ,  RAIS, Yoach

IPC分类号： C12N5/0735 ,  C12N5/074

CPC分类号： C12N5/0611 ,  C12N5/0606 ,  C12N5/0696 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/2306 ,  C12N2501/235 ,  C12N2501/42 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/605 ,  C12N2501/606 ,  C12N2501/727 ,  C12N2501/999

摘要： Provided is an isolated human naive pluripotent stem cell (PSC), wherein: (i) when the naive PSC is a female PSC, then said naive female PSC has two unmethylated alleles of an X-inactive specific transcript (XIST) gene; and (ii) when said naive PSC is a male PSC, then said naive male PSC has an unmethylated allele of said XIST gene. Also provided is a culture medium which comprises an ERK1/2 inhibitor, a GSK3beta inhibitor, a p38 inhibitor, a JNK inhibitor, a STAT3 activator and at least one agent selected from the group consisting of: bFGF, TGFbeta 1, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor; or at least agent selected from the group consisting of: a TGFR inhibitor, a FGFR inhibitor, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor.